Dr. Fauci: (10:03) Thank you very much, Dr. Walensky. I’d like to spend the next couple of minutes in addressing a much underutilized intervention for COVID-19 and that is the use of monoclonal antibodies for the treatment and prevention of SARS-CoV-2 infection and COVID-19 disease. Next slide. For those not totally familiar with this, monoclonal antibody is an antibody that’s produced by a single clone of B cells or a cell line and consists of identical antibody molecules that can actually be produced in the in vitro situation in unlimited quantities. Next slide. If you look at the virion on the upper left part of the slide and you look up the blown up spike protein, the red molecule on the right upper panel. When you talk about polyclonal antibodies which result from infection or vaccination, it’s a group of antibodies against every aspect of the spike protein, which is the good news.
Dr. Fauci: (11:10) However, the concentration and the affinity of those antibodies can be markedly improved if you get a single cloned antibody, hence the word monoclonal, that’s against the very specific part of the spike protein. That can have a major effect in prevention and treatment. Next slide. So let’s look at what we have. We have three anti SARS-CoV-2 monoclonal antibody products that have currently had emergency use authorization from the FDA. And the EUAs here are for adults and children 12 years of age and older who weigh at least 88 pounds. There are three of them. There’s the Lilly product, the Bamlanivimab plus etesevimab, there’s the Regeneron product referred to as REGEN-COV. And then there’s the GSK and Vir product. Each of these products targets the spike protein of SARS-CoV-2. Next slide. So you can do an indication for these antibodies that are twofold.
Dr. Fauci: (12:20) The first is to treat infection with SARS-CoV-2. Next slide. And in this regard, clinical trials have demonstrated that early treatment with anti SARS-CoV-2 monoclonal antibodies can reduce the risk of COVID-19 hospitalization or death by 70 to 85%. It is important to emphasize that this must be done early in infection and not wait, of course, until a person is sick enough to be hospitalized. That’s when you get the best effect. And again, being an underutilized intervention, we want people out there including physicians as well as potential patients to realize the advantage of this very effective way of treating early infection. Next slide. Now, if you look at the people who should benefit from this, this is a list from the FDA and the NIH treatment guidelines about all of the people who may have significant benefit from this type of therapy if given early in their infection. I’m not going to go through each and every one of them. But as you can see, there are a number of conditions on this slide that could benefit from the monoclonal antibody treatment after infection. Next slide.
Dr. Fauci: (13:47) But there’s also the benefit of prevention using monoclonal antibodies. Next slide. And we know now that the FDA, just a couple of weeks ago, authorized the Regeneron monoclonal antibody for post-exposure prophylaxis, namely for the prevention of COVID-19 after someone has been exposed to a documented case of SARS-CoV-2. And even now, and I won’t show the data because of lack of time, there are now studies in pre-exposure prophylaxis, as well as other studies in treatment. So I’ll have on the last slide, next slide, the treatment guidelines panel. We can give you all the information and it’s accessible on the website shown here. And for physicians, patients, and others who want to know how you can get monoclonal antibodies administered, this is the call center, and is the online way to approach it. So bottom line is this is a very effective intervention for COVID-19. It is underutilized, and we recommend strongly that we utilize this to its fullest.
Click herefor the full transcript of today’s White House Covid Task Force Briefing.
+ The New England Journal of Medicine (April 19, 2018): Monoclonal Antibodies for Emerging Infectious Diseases — Borrowing from History, co-authored by Dr. Anthony Fauci, M.D.
“Research advances could facilitate use of monoclonal antibodies for emerging infectious diseases — in treatment of infected individuals, targeted prophylaxis to protect high-risk individuals, and targeted prophylaxis to interrupt transmission in average-risk populations.”
Click here: Interview with Dr. Anthony Fauci on the use of monoclonal antibodies in the context of emerging infectious diseases.(9.5 minutes)
+Thurston County Auditor: Yelm City Council Race Recount Certified – The Thurston County Canvassing Board certified the Yelm City Council Position 4 race which underwent a mandatory manual recount Friday morning. The board certified that Steffen Burney will advance to the General Election in November over Kayla Russel by one vote. The votes did not change from the earlier results.
+ The New York Times: Western Drought Will Last Into Fall or Longer – The forecast, from the National Oceanic and Atmospheric Administration, comes as almost half of the land area of the lower 48 states is experiencing drought.
Editor’s note: Finally, after plenty of monoclonal antibodies have been stored by the U. S. government, hospital systems on the verge of collapse due to COVID-19 overcrowding, are finally giving them a go and mainstream media is covering this story!
These are the same monoclonal antibodies used in the multiple drug cocktail to save the life of President Trump and may keep many from having to go to the hospital.
MONOCLONAL ANTIBODIES NOW ENCOURAGED BY BIDEN ADMIN.
+ Association of American Physicians and Surgeons: Peter McCullough, MD testifies to Texas Senate HHS Committee – Doctors need to treat their COVID-19 patients and if so, an 85% reduction of hospitalizations would ensue.[Ed. note: Dr. McCullough says doctors sending positive tested patients home to wait for symptoms is not TREATING them, which they took an oath to do! Monoclonal antibodies is one of the treatments administered along with an anti-inflammatory, Vit. C & D, and zinc.]
+ The Washington Post: Monoclonal antibodies are a freely available treatment for covid-19 that can prevent severe disease if given early enough to patients. Donald Trump, when he became sick as president, received them. But patients are rarely taking this therapy now. Fewer than 30 percent of eligible patients have taken Regeneron Pharmaceuticals’ monoclonal antibodies, the drug company said. “It is absolutely the standard of care for covid-19,” one infectious-disease pharmacist told The Post. “It is my hope that clinics know that.”Source
Editor’s note: A Yelm City Council Staff report on the STIP buried in the council’s packet is not a public posting to garner comments for a Public Hearing!
The Yelm City Council received the staff’s six-year transportation improvement program (STIP) information packet on August 5, yet there was no public posting prior to their STIP Public Hearing on August 10.
I had asked the city council about this prior to their August 10th meeting. The issue was raised then and Mayor Foster directed the STIP to be publicly posted on Aug. 10. That finally occurred on Aug. 18, 8 days after he directed.
The 2nd and last Public Hearing on the STIP before the council votes their approval is August 24. You may e-mail the council your comments directly.
City Hall leaders continue to tout transparency, yet the public is often left in the dark if someone does not speak up.
Click herefor thesix-year transportation improvement program (STIP)
From The Staff Report:
2022 – 2027 Six-year Transportation Improvement Program
The six-year transportation improvement program (STIP) is the capital facilities document that guides transportation funding for a six-year cycle. The STIP is based on the Yelm Comprehensive Plan and Transportation Plan and is the ‘implementation’ document for the overall plan. Projects that are not on the STIP are not eligible for State or Federal funding, or the use of local Traffic Facilities Charges (TFC’s). Although it is a six-year plan, it is required to be updated annually as projects are completed and new priorities arise.
The proposed 2021 to 2026 list includes: Bald Hill Road reconstruction – City limits to 5 corners. Yelm Prairie Line Trail – Power canal to Roy. Longmire/Yelm Avenue intersection – Traffic control. Mosman Avenue East Phase 3 – 3rd to Clark Road. Coates Avenue connection – Killion to Cullens. Burnett/93rd intersection – Realignment and traffic control. 2nd Street sidewalk improvements – Mosman Ave to Cochrane Park. Mosman Avenue SE reconstruction – 2nd St. to 3rd St. Mosman Avenue Phase 2 – Longmire to Railroad. Yelm Avenue improvements – 1st St. to 4th St. Rhoton Road NW Reconstruction – Railway to Yelm Loop (SR 510 ALT) N.P. Road * Wilkensen Road Reconstruction – 1st Street to Yelm Loop (SR 510 ALT) New additions to the STIP are the Rhoton Road Maintenance items including ADA upgrades and the annual overlay program are also included in the STIP.
“The only update to the STIP from years prior is the reconstruction of Rhoton Road Northwest from Railway Street Southeast to the intersection of the planned Yelm Loop. The project is funded with about $1.2 million from the state and $960,000 in local funds
Projects Scheduled to Start in 2022
“For $634,608 in federal funds and $847,592 in local funds, the city plants to construct a new road connecting Longmire Street with the new Mosman Avenue intersection. It includes the addition of bike lanes, sidewalks, street lighting and stormwater improvements along the corridor. Other improvements in the scope of the project include the construction of a new road from Longmire Street to Solberg Street, and the reconstruction of Mosman Avenue between Solberg Street and Railroad Street.
“The city plans to extend the Yelm Prairie Line Trail to the city of Roy for about $1.5 million in state funds and $75,000 in local funds.
“Construction of a new 5-foot wide multi-use concrete sidewalk along the west side of Second Street Southeast from Cochrane Park to the existing sidewalk at Mosman Avenue would use $160,000 in state funds and $90,000 in local funds.
“For $180,000 from the state and $130,000 from local funding, the city plans to construct sidewalks on both sides of Mosman Avenue Southeast. The project includes intersection treatment at Second Street Southeast and Mosman Avenue Southeast as well as the construction of bike lanes from Second Street Southeast to Third Street Southeast.
“Finally for 2022, the city plans to use $539,280 in federal funds, about $1.3 million in state funds and $464,360 of local funding for the construction and repair or replacement of sidewalks, new parallel parking, intersection treatments and access control channelization features along both sides of Yelm Avenue from First Avenue Southeast to Fourth Avenue Southeast.”